Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Purinergic Receptors: Elucidating the Role of These Immune Mediators in HIV-1 Fusion

Version 1 : Received: 24 January 2020 / Approved: 26 January 2020 / Online: 26 January 2020 (01:28:26 CET)

A peer-reviewed article of this Preprint also exists.

Freeman, T.L.; Swartz, T.H. Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion. Viruses 2020, 12, 290. Freeman, T.L.; Swartz, T.H. Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion. Viruses 2020, 12, 290.

Journal reference: Viruses 2020, 12, 290
DOI: 10.3390/v12030290

Abstract

Purinergic receptors are inflammatory mediators activated by extracellular nucleotides released by dying or injured cells. Several studies have described an important role for these receptors in HIV-1 entry, particularly regarding their activity on HIV-1 viral membrane fusion. Several reports identify purinergic receptor antagonists that inhibit HIV-1 membrane fusion; these drugs are suspected to act through antagonizing Env-chemokine receptor interactions. They also appear to abrogate activity of downstream mediators that potentiate activation of the NLRP3 inflammasome pathway. Here we review the literature on purinergic receptors, the drugs that inhibit their function, and the evidence implicating these receptors in HIV-1 entry.

Subject Areas

fusion; purinergic; HIV-1; P2X1; P2X7

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.